Anjali Agrawal , Smita Salunke , Alfred Rumondor , Karen Thompson , Grazia Caivano , Jennifer Walsh , Brian Enright , Philip Sherratt , Kevin Hughes , David Clapham , Peter Kuehl , on behalf of the International Consortium (IQ) for Innovation and Quality in Pharmaceutical Development and European Paediatric Formulation Initiative (EuPFI)
{"title":"儿科辅料风险评估(PERA)工具及应用,用于选择合适的儿科剂型辅料--第 2 部分。","authors":"Anjali Agrawal , Smita Salunke , Alfred Rumondor , Karen Thompson , Grazia Caivano , Jennifer Walsh , Brian Enright , Philip Sherratt , Kevin Hughes , David Clapham , Peter Kuehl , on behalf of the International Consortium (IQ) for Innovation and Quality in Pharmaceutical Development and European Paediatric Formulation Initiative (EuPFI)","doi":"10.1016/j.ejpb.2024.114447","DOIUrl":null,"url":null,"abstract":"<div><p>It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The “Paediatric Excipient Risk Assessment (PERA)” framework, which proposes a comprehensive approach by considering all relevant factors related to patient, dosage form, and excipient attributes, was developed and published as part 1 of this paper series, to enable the rational selection of excipients for paediatric medicinal products.</p><p>This article is Part 2 of the series and presents the PERA tool that allows easy adoption of the PERA framework. Using a straightforward heat map scoring approach (Red, Yellow, and Green category) for risk evaluation, the PERA tool can be used to compare and choose excipients. The PERA tool will help users identify potential gaps in excipients information that will help with risk-based mitigation planning. Several case studies covering frequently used and novel excipients for oral, as well as the choice of excipient for parenteral products for neonatal administration, serve to illustrate the PERA tool’s usefulness.</p></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"203 ","pages":"Article 114447"},"PeriodicalIF":4.4000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S093964112400273X/pdfft?md5=edfa898d02ffe95b62ec366bfa2f0018&pid=1-s2.0-S093964112400273X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms – Part 2\",\"authors\":\"Anjali Agrawal , Smita Salunke , Alfred Rumondor , Karen Thompson , Grazia Caivano , Jennifer Walsh , Brian Enright , Philip Sherratt , Kevin Hughes , David Clapham , Peter Kuehl , on behalf of the International Consortium (IQ) for Innovation and Quality in Pharmaceutical Development and European Paediatric Formulation Initiative (EuPFI)\",\"doi\":\"10.1016/j.ejpb.2024.114447\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The “Paediatric Excipient Risk Assessment (PERA)” framework, which proposes a comprehensive approach by considering all relevant factors related to patient, dosage form, and excipient attributes, was developed and published as part 1 of this paper series, to enable the rational selection of excipients for paediatric medicinal products.</p><p>This article is Part 2 of the series and presents the PERA tool that allows easy adoption of the PERA framework. Using a straightforward heat map scoring approach (Red, Yellow, and Green category) for risk evaluation, the PERA tool can be used to compare and choose excipients. The PERA tool will help users identify potential gaps in excipients information that will help with risk-based mitigation planning. Several case studies covering frequently used and novel excipients for oral, as well as the choice of excipient for parenteral products for neonatal administration, serve to illustrate the PERA tool’s usefulness.</p></div>\",\"PeriodicalId\":12024,\"journal\":{\"name\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"volume\":\"203 \",\"pages\":\"Article 114447\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S093964112400273X/pdfft?md5=edfa898d02ffe95b62ec366bfa2f0018&pid=1-s2.0-S093964112400273X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S093964112400273X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093964112400273X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms – Part 2
It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The “Paediatric Excipient Risk Assessment (PERA)” framework, which proposes a comprehensive approach by considering all relevant factors related to patient, dosage form, and excipient attributes, was developed and published as part 1 of this paper series, to enable the rational selection of excipients for paediatric medicinal products.
This article is Part 2 of the series and presents the PERA tool that allows easy adoption of the PERA framework. Using a straightforward heat map scoring approach (Red, Yellow, and Green category) for risk evaluation, the PERA tool can be used to compare and choose excipients. The PERA tool will help users identify potential gaps in excipients information that will help with risk-based mitigation planning. Several case studies covering frequently used and novel excipients for oral, as well as the choice of excipient for parenteral products for neonatal administration, serve to illustrate the PERA tool’s usefulness.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.